NTT
25.7.2022 14:02:12 CEST | Business Wire | Press release
NTT Anode Energy Corporation (President and CEO: Teruyuki Kishimoto, Head Office: Minato-ku, Tokyo, NTT Anode Energy) announced a joint research and development project to study safety measures for the mass transportation of hydrogen through existing pipeline infrastructure. The study, being performed in collaboration with the National Institute of Advanced Industrial Science and Technology (President: Kazuhiko Ishimura, Chiyoda-ku, Tokyo AIST) and Toyota Tsusho Co., Ltd. (Representative Director: Ichiro Kashitani, Minato-ku, Tokyo, Toyota Tsusho), is expected to contribute to the realization of a pipeline transportation model for hydrogen that could be implemented globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005285/en/
According to a paper published by the International Renewable Energy Agency , “Hydrogen has emerged as an important part of the clean energy mix needed to ensure a sustainable future.” However, the large-scale, stable transportation of hydrogen through new pipeline infrastructure faces issues including land acquisition construction costs and building time. Utilizing existing pipeline infrastructure can solve these issues, and this new study represents the next step in this model’s proof-of-concept process.
The study will examine a double-piping system in which a hydrogen pipeline is placed in an existing pipe (the “sheath pipe”) buried underground. Factors to be measured and contributed to the formulation of technical standards include:
- On-site investigation of hydrogen leakage detection
- Verification of detection of signs of abnormality
- Establishment of a control sequence to ensure safety
- Performance evaluation of various hydrogen sensors in a real-world environment
Safety measures will be investigated under the assumption of unsteady conditions including rupture accidents and natural disasters during pipeline operation. In addition to examining the safety measures necessary for such use of existing pipelines, the study will verify the profitability of such projects, including cost analysis of transportation; energy input; and economic efficiency, as compared to other hydrogen transportation means.
Based on the knowledge and data gained through this project, NTT Anode Energy and its collaborators will promote and establish technical studies on safety measures for practical use. Ultimately, the project will also support the future supply of hydrogen to urban areas (e.g., public and commercial facilities, data centers and communications buildings; fuel cell vehicles; hydrogen stations, etc.), supply through pipelines utilizing communication pipelines (e.g., cable tunnels) and will contribute to the development of smart cities and the establishment of hydrogen supply means through pipelines in regions with a view to a society that consumes a large amount of hydrogen through the development of CO2-free hydrogen.
This project is being conducted in accordance with the "Research and development for the full-scale popularization of ultra-high pressure hydrogen infrastructure/Research and development for international development, international standardization, etc./Research and study for the examination of technical standards for hydrogen supply infrastructure, etc." of the New Energy and Industrial Technology Development Organization .
Primary Areas of Research by Collaborator
NTT Anode Energy
- Hydrogen leakage detection;
- Abnormal sign detection;
- Hydrogen sensors investigation;
- Investigation of residual hydrogen concentration at the time of hydrogen leakage; and
- Investigation of explosion effect of manhole cover
AIST
- Investigation of fire flame behavior caused by the ignition of leaked hydrogen in a simulated double piping system
Toyota Tsusho
- Clarification of unit costs through verification of equipment, installation and safety costs; and
- Verification of advantageous conditions and business establishment requirements of pipeline transportation
About NTT Anode Energy Group
As a company focused on leveraging the information communications technology and DC power supply technologies of the NTT Group in pursuit of “smart energy” business opportunities, NTT Anode Energy is working to develop and deliver energy solutions that make more sophisticated and efficient use of distributed energy resources such as renewable power generation facilities and storage batteries. In this way, it can fully express the unique synergies of the NTT Group. Through these efforts, we aim to work with partner companies to create new energy distribution mechanisms to help to revitalize industries and shape a more sustainable society.
NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. © 2022 NIPPON TELEGRAPH AND TELEPHONE CORPORATION
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005285/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
